News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amicus Therapeutics, Inc. (FOLD) Presents Updated Patient Screening Profiles From Phase 3 Fabry Study


9/6/2012 9:35:38 AM

CRANBURY, N.J., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced updated details on patients screened for one of the global Phase 3 registration studies (Study 011) to investigate the pharmacological chaperone migalastat HCl for Fabry disease. These results were presented in a poster1 at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2012 (SSIEM 2012).

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES